Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen.

Estrogen is an important vasoprotective molecule that causes the rapid dilation of blood vessels by activating endothelial nitric oxide synthase (eNOS) through an unknown mechanism. In studies of intact ovine endothelial cells, 17beta-estradiol (E2) caused acute (five-minute) activation of eNOS that was unaffected by actinomycin D but was fully inhibited by concomitant acute treatment with specific estrogen receptor (ER) antagonists. Overexpression of the known transcription factor ERalpha led to marked enhancement of the acute response to E2, and this was blocked by ER antagonists, was specific to E2, and required the ERalpha hormone-binding domain. In addition, the acute response of eNOS to E2 was reconstituted in COS-7 cells cotransfected with wild-type ERalpha and eNOS, but not by transfection with eNOS alone. Furthermore, the inhibition of tyrosine kinases or mitogen-activated protein (MAP) kinase kinase prevented the activation of eNOS by E2, and E2 caused rapid ER-dependent activation of MAP kinase. These findings demonstrate that the short-term effects of estrogen central to cardiovascular physiology are mediated by ERalpha functioning in a novel, nongenomic manner to activate eNOS via MAP kinase-dependent mechanisms.

[1]  U. Dirnagl,et al.  Chemiluminescence detection of nitric oxide production from rat cerebral cortical endothelial cells in culture. , 1998, Brain research. Brain research protocols.

[2]  T. Doetschman,et al.  Defective Endothelium-dependent Relaxation of Vascular Smooth Muscle and Endothelial Cell Ca2+ Signaling in Mice Lacking Sarco(endo)plasmic Reticulum Ca2+-ATPase Isoform 3* , 1997, The Journal of Biological Chemistry.

[3]  A. Quyyumi,et al.  The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. , 1997, Circulation.

[4]  G. Garcı́a-Cardeña,et al.  17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. , 1997, Circulation research.

[5]  I. Yuhanna,et al.  Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. , 1997, Circulation research.

[6]  C. Rosenfeld,et al.  Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. , 1997, The American journal of physiology.

[7]  J. Gustafsson,et al.  The novel estrogen receptor‐β subtype: potential role in the cell‐ and promoter‐specific actions of estrogens and anti‐estrogens , 1997, FEBS letters.

[8]  S. Kato,et al.  Rapid activation of MAP kinase by estrogen in the bone cell line. , 1997, Biochemical and biophysical research communications.

[9]  O. Rønnekleiv,et al.  Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A. , 1997, Molecular pharmacology.

[10]  P. Shaul,et al.  Glucocorticoids Downregulate Cyclooxygenase-1 Gene Expression and Prostacyclin Synthesis in Fetal Pulmonary Artery Endothelium via Activation of Endothelial Glucocorticoid Receptors ♦ 116 , 1997, Pediatric Research.

[11]  A. Bilancio,et al.  Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. , 1996, Cancer research.

[12]  S. Hubchak,et al.  Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. , 1996, Circulation.

[13]  D. Vaughan,et al.  Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. , 1996, Circulation.

[14]  A. M. Lefer,et al.  Direct measurement of nitric oxide release from vascular endothelial cells. , 1996, Journal of applied physiology.

[15]  R. Cannon,et al.  Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. , 1996, Circulation.

[16]  P. Ramwell,et al.  The vascular protective effects of estrogen , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[18]  MasayoshiHashimoto,et al.  Modulation of Endothelium-Dependent Flow-Mediated Dilatation of the Brachial Artery by Sex and Menstrual Cycle , 1995 .

[19]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[20]  M. Dunn,et al.  Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. , 1995, Circulation research.

[21]  R. Busse,et al.  Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. , 1995, Circulation research.

[22]  P. Shaul,et al.  Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells. , 1994, American journal of respiratory cell and molecular biology.

[23]  R. Karas,et al.  Estrogen and the blood vessel wall , 1994, Current opinion in cardiology.

[24]  R. Dubey,et al.  Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol mediated NO release. , 1994, Biochemical and biophysical research communications.

[25]  A. Quyyumi,et al.  Acute Vascular Effects of Estrogen in Postmenopausal Women , 1994, Circulation.

[26]  C. Gay,et al.  Specific binding of estrogen to osteoclast surfaces. , 1994, Biochemical and biophysical research communications.

[27]  L. J. Chandler,et al.  Ethanol enhances the endothelial nitric oxide synthase response to agonists. , 1993, Hypertension.

[28]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[29]  D. Herrington,et al.  Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.

[30]  P. Shaul,et al.  Oxygen modulates endothelium-derived relaxing factor production in fetal pulmonary arteries. , 1992, The American journal of physiology.

[31]  J. Sullivan.  Estrogen and coronary heart disease in women. , 1991, JAMA.

[32]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[33]  S. Meizel,et al.  Progesterone acts at the plasma membrane of human sperm , 1991, Molecular and Cellular Endocrinology.

[34]  B. O’Malley,et al.  Steroid receptor family: structure and functions. , 1990, Endocrine reviews.

[35]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[36]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[37]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[38]  C. Hobel,et al.  Serum progesterone and estradiol-17beta levels in premature and term labor. , 1977, American journal of obstetrics and gynecology.

[39]  A. Turnbull,et al.  Significant fall in progesterone and rise in oestradiol levels in human peripheral plasma before onset of labour. , 1974, Lancet.

[40]  A. Turnbull,et al.  SIGNIFICANT FALL IN PROGESTERONE AND RISE IN ŒSTRADIOL LEVELS IN HUMAN PERIPHERAL PLASMA BEFORE ONSET OF LABOUR , 1974 .

[41]  M. Wehling.  Specific, nongenomic actions of steroid hormones. , 1997, Annual review of physiology.

[42]  I. Yuhanna,et al.  Acylation targets endothelial nitric oxide synthase (enos) to plasmalemmal caveolae , 1996 .

[43]  S. Reis,et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.

[44]  P. López-Jaramillo,et al.  The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.